Companies / BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc.
Nasdaq: BBIOCIK 1743881PALO ALTO, CA
Financials ยท FY2025
Ownership
195.5M shares outstanding ยท as of Aug 3, 2026
Ownership
| Insiders | 3.45% | 6,752,817 |
| Institutions | 97.12% | 189,853,518 |
| Public float | 0.00% | 0 |
Reported holdings exceed shares outstanding โ public float shown as 0; some positions may overlap or lag.
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 12
View all โ| Insider | % of shares | Shares |
|---|---|---|
Kumar NeilCEOChief Executive Officer ยท Director | 2.72% | 5,308,584 |
Homcy Charles JDirector | 0.47% | 919,876 |
Trimarchi ThomasPresident and CFO | 0.20% | 395,626 |
Apuli MaricelFormerChief Accounting Officer | 0.07% | 136,115 |
Hassan FredDirector | 0.02% | 29,879 |
Daniels Ronald JDirector | 0.01% | 20,981 |
Momtazee James CDirector | <0.01% | 19,070 |
Ellis AndreaDirector | <0.01% | 18,589 |
Scott Randal W.Director | <0.01% | 11,589 |
Aguiar EricDirector | <0.01% | 10,579 |
Institutional holders 445
View all โ| Holder | Value | % of shares |
|---|---|---|
| $1.29B | 8.63% | |
| $984.76M | 6.78% | |
| $978.61M | 6.74% | |
| $879.42M | 6.06% | |
| $766.19M | 5.26% | |
| $688.29M | 4.60% | |
| $389.30M | 2.60% | |
| $371.93M | 2.52% | |
| $369.55M | 2.47% | |
| $330.39M | 2.27% |
Activity
Jun 30, 2026View all โ
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares ฮ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q3 2025 as of | Farallon Capital Management LLC 13F manager | New | Common stock | $425.49M | +8.2M | 8,192,000 4.19% of shares | high |
| Q2 2026 as of | BlackRock, Inc. 13F manager | Trim | Common stock | $-317.46M | -4.3M -29.30% | 10,287,156 5.26% of shares | high |
| Q1 2026 as of | Viking Global Investors LP 13F manager | Trim | Common stock | $-189.47M | -2.6M -17.73% | 11,842,434 6.06% of shares | high |
| Q1 2026 as of | Janus Henderson Group PLC 13F manager | Add | Common stock | $161.77M | +2.2M +19.80% | 13,179,013 6.74% of shares | high |
| Q1 2026 as of | Norges Bank 13F manager | Exit | Common stock | $-116.80M | -1.5M -100.00% | 0 | high |
| Q1 2026 as of | Two Sigma Investments, LP 13F manager | Add | Common stock | $87.15M | +1.2M +60.28% | 3,120,631 1.60% of shares | high |
| Q4 2025 as of | Farallon Capital Management LLC 13F manager | Add | Common stock | $61.69M | +806K +9.84% | 8,998,463 4.60% of shares | high |
| Q1 2026 as of | Millennium Management LLC 13F manager | Add | Common stock | $44.31M | +597K +1630.99% | 633,283 0.32% of shares | medium |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Vanguard Group Inc | Passive13G/A | โ |
| Janus Henderson Group PLC | Passive13G | โ |
| Farallon Capital Partners, L.P. | Passive13G | โ |
| Janus Henderson Group PLC | Passive13G/A | โ |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| BBIO | โ | 10806X102 |